Ryvu Therapeutics SA Total Assets

Latest as of March 2026: zł200.96 Million PLN ≈ $55.31 Million USD

Ryvu Therapeutics SA total assets. Based on the latest financial reports, Ryvu Therapeutics SA (RVU) holds total assets worth zł200.96 Million PLN (≈ $55.31 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ryvu Therapeutics SA (RVU) total market value for the company's overall valuation and market capitalisation.

Total Assets of Ryvu Therapeutics SA (2010–2025)

Total assets of Ryvu Therapeutics SA from 2010 to 2025. This chart illustrates how Ryvu Therapeutics SA's total assets have evolved over time, based on quarterly financial data. See Ryvu Therapeutics SA share price for real-time trading data and today's change.

Ryvu Therapeutics SA - Asset Composition Analysis

Ryvu Therapeutics SA Total Assets Breakdown (December 2025)

Ryvu Therapeutics SA total assets breakdown as of December 2025. Ryvu Therapeutics SA's total assets of zł200.96 Million consist of 62.0% current assets and 38.0% non-current assets.

Asset Category	Amount (PLN)	% of Total Assets
Cash & Equivalents	zł0.00	26.6%
Accounts Receivable	zł20.10 Million	9.0%
Inventory	zł1.33 Million	0.6%
Property, Plant & Equipment	zł0.00	0.0%
Intangible Assets	zł6.04 Million	2.7%
Goodwill	zł0.00	0.0%

Asset Composition Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RVU net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Ryvu Therapeutics SA's current assets represent 62.0% of total assets in 2025, an increase from 24.9% in 2010.
Cash Position: Cash and equivalents constituted 26.6% of total assets in 2025, up from 3.2% in 2010.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2010.
Asset Diversification: The largest asset category is accounts receivable at 9.0% of total assets.

Ryvu Therapeutics SA Competitors by Total Assets

Key competitors of Ryvu Therapeutics SA based on total assets are shown below.

Company	Country	Total Assets
Biomarin Pharmaceutical Inc NASDAQ:BMRN	USA	$11.72 Billion
HLB Co. Ltd KQ:028300	Korea	₩925.44 Billion
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Shanghai Medicilon Inc SHG:688202	China	CN¥2.88 Billion
Blue Jet Healthcare Limited NSE:BLUEJET	India	Rs16.41 Billion
Hangzhou Biotest Biotech Co Ltd SHG:688767	China	CN¥2.49 Billion
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	China	CN¥725.73 Million
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	China	CN¥3.67 Billion

Ryvu Therapeutics SA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.26	3.17	4.61
Quick Ratio	2.23	3.16	4.49
Cash Ratio	0.00	0.00	0.00
Working Capital	zł65.15 Million	zł153.56 Million	zł99.25 Million

Ryvu Therapeutics SA - Advanced Valuation Insights

This section examines the relationship between Ryvu Therapeutics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	9.71
Latest Market Cap to Assets Ratio	0.48
Asset Growth Rate (YoY)	-40.7%
Total Assets	zł224.44 Million
Market Capitalization	$108.04 Million USD

Valuation Analysis

Below Book Valuation: The market values Ryvu Therapeutics SA's assets below their book value (0.48x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Ryvu Therapeutics SA's assets decreased by 40.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual total assets of Ryvu Therapeutics SA from 2010 to 2025.

Year	Total Assets	Change
2025-12-31	zł224.44 Million ≈ $61.77 Million	-40.75%
2024-12-31	zł378.78 Million ≈ $104.24 Million	-6.06%
2023-12-31	zł403.20 Million ≈ $110.97 Million	-15.11%
2022-12-31	zł474.98 Million ≈ $130.72 Million	+107.58%
2021-12-31	zł228.81 Million ≈ $62.97 Million	-22.60%
2020-12-31	zł295.64 Million ≈ $81.36 Million	+61.65%
2019-12-31	zł182.89 Million ≈ $50.33 Million	-28.47%
2018-12-31	zł255.70 Million ≈ $70.37 Million	+146.88%
2017-12-31	zł103.57 Million ≈ $28.50 Million	+16.22%
2016-12-31	zł89.12 Million ≈ $24.53 Million	+36.60%
2015-12-31	zł65.24 Million ≈ $17.96 Million	+143.41%
2014-12-31	zł26.80 Million ≈ $7.38 Million	+49.09%
2013-12-31	zł17.98 Million ≈ $4.95 Million	+17.13%
2012-12-31	zł15.35 Million ≈ $4.22 Million	-12.31%
2011-12-31	zł17.50 Million ≈ $4.82 Million	+70.44%
2010-12-31	zł10.27 Million ≈ $2.83 Million	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$108.04 Million

zł392.58 Million PLN

Market Cap Rank

#18711 Global

#142 in Poland

Share Price

zł16.98

Change (1 day)

-4.61%

52-Week Range

zł13.76 - zł29.90

All Time High

zł75.00